Literature DB >> 16533828

Pilot study of continuous infusion cefepime in adult patients with cystic fibrosis.

Emily E Han, Paul M Beringer, Pål Falck, Stan Louie, Purush Rao, Bertrand Shapiro, Mark Gill.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16533828     DOI： 10.1093/jac/dkl053

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  6 in total

Review 1.  Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.

Authors:  Charlotte Roy; Manon Launay; Sophie Magréault; Isabelle Sermet-Gaudelus; Vincent Jullien
Journal:  Clin Pharmacokinet       Date:  2021-01-24       Impact factor: 6.447

2.  Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.

Authors:  William A Prescott; Allison E Gentile; Jerod L Nagel; Rebecca S Pettit
Journal:  P T       Date:  2011-11

3.  Relationship of Pulmonary Outcomes, Microbiology, and Serum Antibiotic Concentrations in Cystic Fibrosis Patients.

Authors:  Andrea Hahn; Caroline Jensen; Hani Fanous; Hollis Chaney; Iman Sami; Geovanny F Perez; Stan Louie; Anastassios C Koumbourlis; James E Bost; John N van den Anker
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Sep-Oct

4.  Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses.

Authors:  Mehdi El Hassani; Jean-Alexandre Caissy; Amélie Marsot
Journal:  Clin Pharmacokinet       Date:  2021-01-15       Impact factor: 6.447

5.  Pharmacokinetics of Continuous Infusion Beta-lactams in the Treatment of Acute Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis.

Authors:  Lisa T Hong; Theodore G Liou; Rishi Deka; Jordan B King; Vanessa Stevens; David C Young
Journal:  Chest       Date:  2018-06-13       Impact factor: 9.410

6.  Changes in microbiome diversity following beta-lactam antibiotic treatment are associated with therapeutic versus subtherapeutic antibiotic exposure in cystic fibrosis.

Authors:  Andrea Hahn; Hani Fanous; Caroline Jensen; Hollis Chaney; Iman Sami; Geovanny F Perez; Anastassios C Koumbourlis; Stan Louie; James E Bost; John N van den Anker; Robert J Freishtat; Edith T Zemanick; Keith A Crandall
Journal:  Sci Rep       Date:  2019-02-22       Impact factor: 4.379
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.